Kriya Therapeutics, a biotech company focused on gene therapy, has secured a $313 million funding round, marking a significant financial boost for its development programs. Operating between North Carolina and California, Kriya is advancing treatments targeting genetic diseases utilizing cutting-edge gene editing and delivery technologies. This capital injection will accelerate clinical and preclinical research activities, expanding the company’s pipeline and strengthening its position in the competitive gene therapy sector. The funding reflects ongoing investor confidence in transformative genetic medicine approaches.